| Ytd | -6.05% | |
| 1y | -7.12% |
| Open | 3.20 | Prev Close | 3.15 | Low | 3.20 | High | 3.29 | Mkt Cap | 588.81M |
| Vol | 0.00 | Avg Vol | 3.36M | EPS | -1.06 | P/E | -3.08 | Forward P/E | -3.96 |
| Beta | 2.67 | Short Ratio | 5.85 | Inst. Own | 44.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.27 | 200-d Avg | 3.63 | 1yr Est | 6.50 |
PRME News
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a l
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/
Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Med
Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: Quid
Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgrad
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: P
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Com
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechno
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Conse
CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechn
MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Co
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.